Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

#4305

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Aim(s): We evaluated the efficacy of lenvatinib at lower doses.

Materials and methods: Retrospective multinational cohort of pts with advanced and progressive G1-3 GEP or thoracic NETs treated with lenvatinib. The primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS) and tolerability.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,